

Date: 05th May, 2025

To

BSE LIMITED

Corporate Relations Department

Phiroze Jeejeebhoy Towers

Dalal Street, Fort

Mumbai-400001

Scrip code: 543264

NATIONAL STOCK EXCHANGE OF INDIA

LIMITED

Listing Department

Exchange Plaza, 5th Floor, Plot no. C/1

G Block, Bandra Kurla Complex, Bandra (E)

Mumbai-400051

Scrip Code: NURECA

Subject: Outcome of Board Meeting under Regulation 30 and 33 of Securities and Exchange Board of India ("SEBI") (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("LODR Regulations")

Dear Sir/Ma'am,

We wish to inform you that the Board of Directors of Nureca Limited ("Company") at the meeting held today i.e. May 05, 2025 have:

1. Approved the Audited Financial Results (Standalone and Consolidated) for the quarter and year ended March 31, 2025. A copy of the Audited Financial Results along with Statutory Auditors' Reports with unmodified opinion are enclosed herewith.

A declaration pursuant to Regulation 33(3)(d) of LODR Regulations regarding unmodified opinion of the Statutory Auditors on the audited financial results (Standalone and Consolidated) for the year ended March 31, 2025 is enclosed herewith.

2. Appointed M/s Singhi & Co, Chartered Accountants (FRN 302049E) as the Statutory Auditors of the Company for a period of 5 (Five) consecutive years from the conclusion of the ensuing 9th Annual General Meeting ("AGM") till the conclusion of 14th AGM, subject to approval of the members of the Company at the ensuing AGM, in place of M/s B S R & Co. LLP, Chartered Accountants, whose term is completing at the conclusion of the ensuing 9th AGM of the Company. The details required to be furnished under Regulation 30 of LODR Regulations read with SEBI Master Circular no. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024 as amended upto date ("Master Circular"), is furnished hereunder as **Annexure 1**.

3. Approved the appointment of M/s MGSG and Associates, Chartered Accountants as Internal Auditor of the Company for Financial Year ("FY") 2025-26. The details required to be

NURECA LIMITED

Correspondence Office : SCO 6-7-8, 1st Floor, Madhya Marg, Sector 9-D, Chandigarh 160009
Registered Office : 101 Office Number, Udyog Bhavan, 1st Floor, Sonawala Lane, Goregaon East,
Mumbai City Maharashtra - 400063
Phone No. +91-172-5292900 CIN L24304MH2016PLC320868

furnished under Regulation 30 of LODR Regulations read with Master Circular, is furnished hereunder as **Annexure 2**.

4. Approved the appointment of M/s A. Arora & Company, Practicing Company Secretaries as Secretarial Auditor of the Company for Audit period of five consecutive years commencing from FY 2025-26 till FY 2029-2030, subject to approval of the shareholders of the Company at the ensuing 9th AGM. The details required to be furnished under Regulation 30 of LODR Regulations read with Master Circular, is furnished hereunder as **Annexure 3**.

5. In – principally approved the merger of Nureca Technologies Private Limited, wholly owned subsidiary of the Company with Nureca Limited (“Holding Company”), subject to necessary statutory and regulatory approvals under applicable laws. The Board has delegated the power to Management Committee of the Company to complete the procedures, compliances and matters incidental thereto to give effect to the said merger. The details required to be furnished under Regulation 30 of LODR Regulations read with Master Circular, is furnished hereunder as **Annexure 4**.

6. Approved the re-appointment of Ms. Charu Singh (DIN:07822158) as an Independent Director of the company for the second term of five consecutive years. The details required to be furnished under Regulation 30 of LODR Regulations read with Master Circular, is furnished hereunder as **Annexure 5**.

7. Approved re-appointment of Ms. Ruchita Agarwal (DIN:08941249) as an Independent Director of the company for the second term of five consecutive years. The details required to be furnished under Regulation 30 of LODR Regulations read with Master Circular, is furnished hereunder as **Annexure 6**.

8. Approved re-appointment of Mr. Vijay Kumar Sharma (DIN:02449088) as an Independent Director of the company for the second term of five consecutive years. The details required to be furnished under Regulation 30 of LODR Regulations read with Master Circular, is furnished hereunder as **Annexure 7**.

9. Approved re-appointment of Mr. Rajinder Sharma (DIN:00317133) as Whole Time Director of the Company for a period of five years. The details required to be furnished under Regulation 30 of LODR Regulations read with Master Circular, is furnished hereunder as **Annexure 8**.

10. Approved re-appointment of Mr. Saurabh Goyal, Director (DIN:00136037), who retire by rotation in the ensuing 9th AGM. The details required to be furnished under Regulation 30 of LODR Regulations read with Master Circular, is furnished hereunder as **Annexure 9**.

NURECA LIMITED

Correspondence Office : SCO 6-7-8, 1st Floor, Madhya Marg, Sector 9-D, Chandigarh 160009
Registered Office : 101 Office Number, Udyog Bhavan, 1st Floor, Sonawala Lane, Goregaon East,
Mumbai City Maharashtra - 400063
Phone No. +91-172-5292900 CIN L24304MH2016PLC320868

11. Approved to convene the AGM and Book Closure as under:

The 9th AGM of the Members of the Company will be held on Monday, June 16, 2025 through video conferencing (VC) or other audio visual means (OAVM).

The Register of Members and Share Transfer Books of the Company will be closed from Tuesday, June 10, 2025 till Monday, June 16, 2025 (both days inclusive) for the purpose of AGM. Accordingly, the cut-off date, to ascertain the eligibility of members for remote e-voting / e-voting at AGM, will be Monday, June 9, 2025 i.e. the date prior to the commencement of book closure.

The Board Meeting commenced at 16:30 PM and concluded at 18:25 PM.

This is for your kind information and records please.

Thanking You,

Yours Sincerely,
For **Nureca Limited**

(Nishu Kansal)
Company Secretary & Compliance Officer

NURECA LIMITED

Correspondence Office : SCO 6-7-8, 1st Floor, Madhya Marg, Sector 9-D, Chandigarh 160009
Registered Office : 101 Office Number, Udyog Bhavan, 1st Floor, Sonawala Lane, Goregaon East,
Mumbai City Maharashtra - 400063
Phone No. +91-172-5292900 CIN L24304MH2016PLC320868

Annexure-1

Disclosure pursuant to Schedule III of SEBI LODR Regulations read with Master Circular

Sr. No.	Particulars	Description
1	Name of the Firm	M/s. Singhi & Co, Chartered Accountants (“the Firm”)
2	Reason for Change	The term of existing Statutory Auditors M/s B S R & Co. LLP, Chartered Accountants, (Firm registration no. 101248W/W-100022) is completing at the ensuing 9 th AGM of the Company. Hence, Board of Directors of the Company in its meeting held on 05 th May, 2025 considered and approved the appointment of M/s Singhi & Co, Chartered Accountants (FRN 302049E) as Statutory Auditors pursuant to Section 139 of the Companies Act, 2013 and other applicable provisions, in place of retiring auditors, subject to approval of the members in the ensuing 9 th AGM.
3	Date of appointment	From the conclusion of 9 th AGM
4	Term of Appointment	For a period of 5 (Five) consecutive years from the conclusion of the ensuing 9 th AGM to be held in 2025 till the conclusion of 14 th AGM to be held in 2030, subject to approval of the members of the Company in the ensuing 9 th AGM.
5	Brief Profile (Area of Services)	Singhi & Co, Chartered Accountant has been in the profession for over 80 years and is one of the well-respected audit firms in the country. They provide varied services which include assurance, risk advisory, taxation, corporate finance, etc. They serve multiple listed companies and have tremendous experience in the field of audit. Singhi & Co. has over 26 partners with 8 offices across the country. They are Indian members of Moore Global network.
6	Disclosure of relationships between directors (in case of appointment of director)	Not related

NURECA LIMITED

Correspondence Office : SCO 6-7-8, 1st Floor, Madhya Marg, Sector 9-D, Chandigarh 160009
Registered Office : 101 Office Number, Udyog Bhavan, 1st Floor, Sonawala Lane, Goregaon East, Mumbai City Maharashtra - 400063
Phone No. +91-172-5292900 CIN L24304MH2016PLC320868

Annexure-2

Disclosure pursuant to Schedule III of SEBI LODR Regulations read with Master Circular

Sr. No.	Particulars	Description
1	Name of the Firm	M/s. MGSG and Associates, Chartered Accountants ("the Firm")
2	Reason for Change	Appointment of Internal Auditors. The Company believes that changing the internal auditors will provide a different opinion and practices to have a different insight in the internal controls of the company.
3	Date of appointment	5 th May, 2025
4	Term of Appointment	FY 2025-26
5	Brief Profile (Area of Services)	MGSG and Associates is the pioneer of consulting, accounting, financial advisory and taxation aiming to provide the highest quality of services to its client. Their services have been developed considering best industry practices, business needs and understanding of the Indian market requirements.
6	Disclosure of relationships between directors (in case of appointment of director)	Not related

NURECA LIMITED

Correspondence Office : SCO 6-7-8, 1st Floor, Madhya Marg, Sector 9-D, Chandigarh 160009
 Registered Office : 101 Office Number, Udyog Bhavan, 1st Floor, Sonawala Lane, Goregaon East,
 Mumbai City Maharashtra - 400063
 Phone No. +91-172-5292900 CIN L24304MH2016PLC320868

Annexure-3

Disclosure pursuant to Schedule III of SEBI LODR Regulations read with Master Circular

Sr. No.	Particulars	Description
1	Name of the Firm	M/s A. Arora & Company, Practicing Company Secretaries.
2	Reason for Change	Enhanced corporate governance and as per the requirements of LODR Regulations.
3	Date of appointment	5 th May, 2025
4	Term of Appointment	Five consecutive years commencing from FY 2025-26 till FY 2029-2030, subject to approval of the shareholders in the ensuing 9th AGM.
5	Brief Profile (Area of Services)	<p>A Arora & Co is a sole proprietorship firm registered as a practicing company secretaries firm with the Institute of Company Secretaries of India (ICSI) for over 3 decades.</p> <p>It has immense knowledge and experience in dealing with matters relating to Company Law, Securities Laws, Due Diligence, and Capital Market Transactions, serving as consultants and auditors to a wide range of companies including listed, unlisted public and private companies and several government companies/ corporations for several years.</p> <p>A. Arora & Co's key offerings other than Secretarial Audit functions also include setting up companies, approvals from all the government departments including approvals from the Registrar of Companies, Regional Director-Ministry of Corporate Affairs, Reserve Bank of India (RBI), Foreign Exchange Regulations.</p>
6	Disclosure of relationships between directors (in case of appointment of director)	Not related

NURECA LIMITED

Correspondence Office : SCO 6-7-8, 1st Floor, Madhya Marg, Sector 9-D, Chandigarh 160009
Registered Office : 101 Office Number, Udyog Bhavan, 1st Floor, Sonawala Lane, Goregaon East, Mumbai City Maharashtra - 400063
Phone No. +91-172-5292900 CIN L24304MH2016PLC320868

Annexure 4

Disclosure pursuant to Schedule III of SEBI LODR Regulations read with Master Circular

Particulars	Details
Name of the entity(ies) forming part of the amalgamation/merger, details in brief such as size, turnover etc.	Transferee company - Nureca Limited or the Company
	Revenue for the year ended 31 st March 2025 (Standalone) (Rs. In millions)
	Net worth as on 31 st March 2025 (Standalone) (Rs. In millions)
	1146.40 1917.38
	Transferor Company (Wholly Owned Subsidiary of the Company) - Nureca Technologies Private Limited
	Revenue for the year ended 31 st March 2025 (Standalone) (Rs. In millions)
	Net worth as on 31 st March 2025 (Standalone) (Rs. In millions)
	228.14 53.94
Whether the transaction would fall within related party transactions? If yes, whether the same is done at "arm's length"	<p>The scheme involves the amalgamation of wholly owned subsidiary company with the holding company. Therefore, it is exempted as per Regulation 23(5) of the LODR Regulations and the Scheme is also exempt from the provisions of SEBI Master Circular No. SEBI/HO/CFD/POD-2/P/CIR/2023/93 dated June 20, 2023.</p> <p>Furthermore, in accordance with the General Circular No. 30/2014 dated July 17, 2024, issued by the MCA, transactions resulting from compromises, arrangements, and amalgamations under the Companies Act, 2013 are not subjected to the requirements of Section 188 of Companies Act, 2013.</p> <p>As the Transferor Company, being Wholly Owned Subsidiary of the company, is proposed to be amalgamated with the Company through the Scheme, there will be no issue of shares by the Transferee Company. Accordingly, no valuation will be required.</p>

NURECA LIMITED

Correspondence Office : SCO 6-7-8, 1st Floor, Madhya Marg, Sector 9-D, Chandigarh 160009
Registered Office : 101 Office Number, Udyog Bhavan, 1st Floor, Sonawala Lane, Goregaon East, Mumbai City Maharashtra - 400063
Phone No. +91-172-5292900 CIN L24304MH2016PLC320868

	Therefore, requirement of arm's length criteria is not applicable.
Area of business of the entity(ies)	<p>The Transferor Company-</p> <p>Nureca Technologies Private Limited is in the Business of manufacturing, Import, Export, processing, packing, re-packing, trading in, purchase, sell and/ or to act as mercantile agents, clearing and forwarding agents, brokers, consignors, consignees, conversion agents, distributors, act as stockiest or processors and or dealers or service provider in all or any types of medical/ health related consumer goods, pharmaceuticals, Chemicals, Health Electronic items/ components /accessories.</p> <p>The Transferee Company-</p> <p>NURECA LIMITED deals to manufacture formulate, process, develop, refine, import, export, wholesale, and /or retail trade all kinds of pharmaceuticals, drugs, medical or diagnostic equipments.</p>
Rationale for amalgamation/merger	<p>The merger will lead to improved efficiency in the overall combined business including eliminating inter corporate dependencies, minimize the administrative compliances and to maximize shareholders value.</p> <p>The merger will result in reduction in overheads including administrative, managerial and other expenditure and optimal utilization of resources by elimination of unnecessary duplication of activities and related costs.</p> <p>Simplification of group structure by eliminating multiple companies within the group.</p>
In case of cash consideration-amount or otherwise share exchange ratio	Since the Transferor company is wholly owned subsidiary of the Transferee Company, no shares of the Transferee Company shall be allotted under the scheme.
Brief details of change in shareholding pattern(if any) of listed entity.	There will be no change in the shareholding pattern of the Company pursuant to the merger as no shares are being issued by the company with the Scheme.

NURECA LIMITED

Correspondence Office : SCO 6-7-8, 1st Floor, Madhya Marg, Sector 9-D, Chandigarh 160009
Registered Office : 101 Office Number, Udyog Bhavan, 1st Floor, Sonawala Lane, Goregaon East, Mumbai City Maharashtra - 400063
Phone No. +91-172-5292900 CIN L24304MH2016PLC320868

Annexure-5

Disclosure pursuant to Schedule III of SEBI LODR Regulations read with Master Circular

Sr. No.	Particulars	Description
1	Reason for Change	Re-appointment
2	Date of appointment	October 21, 2025
3	Term of Appointment	Re-Appointment of Ms. Charu Singh as an Independent Director of the Company for a period of 5 consecutive years w.e.f. October 21, 2025 to October 21, 2030, being not liable to retire by rotation.
4	Brief Profile (Area of Services)	<p>Ms. Charu officially assumed the role of Director within our Company on October 21, 2020. With a professional history spanning over seven years in accounts and finance, she has accrued valuable experience at Price Waterhouse & Co and GE India Business Services, notably as Assistant Manager for India Transfer Pricing CoE. Additionally, she has contributed as an Ad-Hoc Assistant Professor in the Department of Commerce at Vivekananda College. Her academic credentials encompass a Bachelor's degree in Commerce from the University of Delhi, a Master's degree in Commerce specialising in Business Policy and Corporate Governance from IGNOU, and an MBA in International Business from Punjab University.</p> <p>She further enhances her qualifications with certification as a company secretary from the Institute of Company Secretaries of India.</p>
5	Disclosure of relationships between directors (in case of appointment of director)	She does not have any relationship with any other director of the Company.

NURECA LIMITED

Correspondence Office : SCO 6-7-8, 1st Floor, Madhya Marg, Sector 9-D, Chandigarh 160009
Registered Office : 101 Office Number, Udyog Bhavan, 1st Floor, Sonawala Lane, Goregaon East,
Mumbai City Maharashtra - 400063
Phone No. +91-172-5292900 CIN L24304MH2016PLC320868

6	Enforcement of SEBI orders regarding appointment of directors by listed companies pursuant to Circular No. LIST COMP 74 '2018-19 dated June 20, 2018.	Ms. Charu Singh is not debarred from holding the office of Director by virtue of any SEBI order or such other authority and the Company is in receipt of declaration by her regarding the same.
---	---	---

Annexure-6

Disclosure pursuant to Schedule III of SEBI LODR Regulations read with Master Circular

Sr. No.	Particulars	Description
1	Reason for Change	Re-appointment
2	Date of appointment	October 29, 2025
3	Term of Appointment	Re-Appointment of Ms. Ruchita Agarwal as an Independent Director of the Company for a period of 5 years w.e.f. October 29, 2025 to October 29, 2030, being not liable to retire by rotation.
4	Brief Profile (Area of Services)	Ms. Ruchita has served as a Director of our Company since October 29, 2020. With experience at J.P. Morgan Chase and Dow Jones Consulting, she brings over five years of expertise to her role. She holds a Bachelor's degree in Commerce from the University of Pune and a Global MBA specialising in Finance from the S.P. Jain Center of Management, Singapore.
5	Disclosure of relationships between directors (in case of appointment of director)	She does not have any relationship with any other director of the Company.
6	Enforcement of SEBI orders regarding appointment of directors by listed companies pursuant to Circular No. LIST COMP 74 '2018-19 dated June 20, 2018.	Ms. Ruchita Agarwal is not debarred from holding the office of Director by virtue of any SEBI order or such other authority and the Company is in receipt of declaration by her regarding the same.

NURECA LIMITED

Correspondence Office : SCO 6-7-8, 1st Floor, Madhya Marg, Sector 9-D, Chandigarh 160009
Registered Office : 101 Office Number, Udyog Bhavan, 1st Floor, Sonawala Lane, Goregaon East, Mumbai City Maharashtra - 400063
Phone No. +91-172-5292900 CIN L24304MH2016PLC320868

Annexure-7

Disclosure pursuant to Schedule III of SEBI LODR Regulations read with Master Circular

Sr. No.	Particulars	Description
1	Reason for Change	Re-appointment
2	Date of appointment	October 21, 2025
3	Term of Appointment	Re-Appointment of Mr. Vijay Kumar Sharma as an Independent Director of the Company for a period of 5 years w.e.f. October 21, 2025 to October 21, 2030, being not liable to retire by rotation.
4	Brief Profile (Area of Services)	<p>Mr. Sharma has been a director of our company since October 21, 2020. Prior to this role, he served as the Managing Director and Chief Executive Officer of LIC Housing Finance Limited from 2010 to 2013. Subsequently, in 2013, he assumed the role of Managing Director at the Life Insurance Corporation of India, eventually ascending to the position of Chairman from 2016 to 2018.</p> <p>Additionally, he holds positions on the boards of Reliance Power Limited, Tata Steel Limited, and Mahindra & Mahindra Financial Services Ltd.</p>
5	Disclosure of relationships between directors (in case of appointment of director)	He does not have any relationship with any other director of the Company.
6	Enforcement of SEBI orders regarding appointment of directors by listed companies pursuant to Circular No. LIST COMP 74 '2018-19 dated June 20, 2018.	Mr. Vijay Kumar Sharma is not debarred from holding the office of Director by virtue of any SEBI order or such other authority and the Company is in receipt of declaration by him regarding the same.

NURECA LIMITED

Correspondence Office : SCO 6-7-8, 1st Floor, Madhya Marg, Sector 9-D, Chandigarh 160009
 Registered Office : 101 Office Number, Udyog Bhavan, 1st Floor, Sonawala Lane, Goregaon East,
 Mumbai City Maharashtra - 400063
 Phone No. +91-172-5292900 CIN L24304MH2016PLC320868

Annexure-8

Disclosure pursuant to Schedule III of SEBI LODR Regulations read with Master Circular

Sr. No.	Particulars	Description
1	Reason for Change	Re-appointment
2	Date of appointment	May 28, 2025
3	Term of Appointment	Re-Appointment of Mr. Rajinder Sharma as Whole-time Director of the Company for a period of 5 years w.e.f. May 28, 2025 to May 28, 2030, being liable to retire by rotation.
4	Brief Profile (Area of Services)	Administration and General Management
5	Disclosure of relationships between directors (in case of appointment of director)	He does not have any relationship with any other director of the Company
6	Enforcement of SEBI orders regarding appointment of directors by listed companies pursuant to Circular No. LIST COMP 74 '2018-19 dated June 20, 2018.	Mr. Rajinder Sharma is not debarred from holding the office of Director by virtue of any SEBI order or such other authority and the Company is in receipt of declaration by him regarding the same.

NURECA LIMITED

Correspondence Office : SCO 6-7-8, 1st Floor, Madhya Marg, Sector 9-D, Chandigarh 160009
 Registered Office : 101 Office Number, Udyog Bhavan, 1st Floor, Sonawala Lane, Goregaon East,
 Mumbai City Maharashtra - 400063
 Phone No. +91-172-5292900 CIN L24304MH2016PLC320868

Annexure 9

Disclosure pursuant to Schedule III of SEBI LODR Regulations read with Master Circular

Sr. No.	Particulars	Description
1	Reason for Change	Retire by rotation
2	Date of appointment	Date of AGM
3	Term of Appointment	Re-appointment of Mr. Saurabh Goyal who retire by rotation in the ensuing AGM.
4	Brief Profile (Area of Services)	A seasoned professional, Saurabh oversees external and internal customer interactions while driving operational efficiencies. With a master's degree in Science from King's College, London, and over a decade of experience in the healthcare and life sciences industry, his exceptional organisational abilities have played a pivotal role in positioning Nureca as a leader in the global digital healthcare devices market.
5	Disclosure of relationships between directors (in case of appointment of director)	He does not have any relationship with any other director of the Company except Mr. Aryan Goyal, being his Brother
6	Enforcement of SEBI orders regarding appointment of directors by listed companies pursuant to Circular No. LIST COMP 74 '2018-19 dated June 20, 2018.	Mr. Saurabh Goyal is not debarred from holding the office of Director by virtue of any SEBI order or such other authority and the Company is in receipt of declaration by him regarding the same.

NURECA LIMITED

Correspondence Office : SCO 6-7-8, 1st Floor, Madhya Marg, Sector 9-D, Chandigarh 160009
Registered Office : 101 Office Number, Udyog Bhavan, 1st Floor, Sonawala Lane, Goregaon East, Mumbai City Maharashtra - 400063
Phone No. +91-172-5292900 CIN L24304MH2016PLC320868

NURECA LIMITED						
Office Number 101, 1st Floor Udyog Bhavan Sonawala Lane, Goregaon (East), Mumbai - 400063, Maharashtra, India Tel: +91 -172-5292900, E-mail: cs@nureca.com, Website: www.nureca.com Corporate Identification Number: L24304MH2016PLC320868						
(Amount in INR million, unless otherwise stated)						
Statement of Audited Standalone Financial Results for the Quarter and Year ended 31 March 2025						
Sr. No.	Particulars	Quarter ended			Year ended	
		31 March 2025 (Refer note 3)	31 December 2024 (Unaudited)	31 March 2024 (Refer note 3)	31 March 2025 (Audited)	31 March 2024 (Audited)
1	Revenue from operations	317.50	272.08	195.63	1,146.40	945.21
2	Other income	19.98	15.18	(12.49)	125.40	105.64
3	Total income (1+2)	337.48	287.26	183.14	1,271.80	1,050.85
4	Expenses					
	Purchase of stock-in-trade	308.78	208.97	128.17	864.89	631.90
	Changes in inventories of stock-in-trade	(101.86)	(16.51)	23.49	(68.04)	41.56
	Employee benefits expense	39.82	36.00	29.09	143.56	115.66
	Finance costs	5.94	1.41	1.71	11.15	4.60
	Depreciation and amortization expense	4.75	4.93	5.64	21.53	22.42
	Other expenses	65.07	90.94	62.46	303.31	267.40
	Total expenses	322.50	325.74	250.56	1,276.40	1,083.54
5	Profit/(Loss) before income tax (3-4)	14.98	(38.48)	(67.42)	(4.60)	(32.69)
6	Tax expense					
	- Current tax	(20.85)	(2.88)	(0.46)	(11.98)	13.52
	- Deferred tax	15.11	(2.71)	(22.82)	14.06	(21.79)
7	Profit/(Loss) after income tax (5-6)	20.72	(32.89)	(44.14)	(6.68)	(24.42)
8	Other comprehensive income					
A	(i) Item that will not be reclassified to profit or loss	3.45	0.13	1.10	3.85	0.52
	(ii) Income tax relating to items that will not be reclassified to profit or loss	(0.87)	(0.03)	(0.28)	(0.97)	(0.13)
B	(i) Item that will be reclassified to profit or loss	-	-	-	-	-
	(ii) Income tax relating to items that will be reclassified to profit or loss	-	-	-	-	-
	Other comprehensive income for the period (net of tax)	2.58	0.10	0.82	2.88	0.39
9	Total comprehensive income/(loss) for the period (7+8)	23.30	(32.79)	(43.31)	(3.80)	(24.03)
10	Earning per share of Rs. 10 each					
	- Basic and diluted (in rupees) (not annualized)	2.07	(3.29)	(4.41)	(0.67)	(2.44)
11	Paid-up equity share capital (Face value of share - Rs.10 each)	100.00	100.00	100.00	100.00	100.00
12	Other equity				1,824.79	1,828.59
	See accompanying notes to the audited standalone financial results					

SAURABH GOYAL Digitally signed by
SAURABH GOYAL
Date: 2025.05.05
20:21:31 +05'30'

NURECA LIMITED

Correspondence Office : SCO 6-7-8, 1st Floor, Madhya Marg, Sector 9-D, Chandigarh 160009
Registered Office : 101 Office Number, Udyog Bhavan, 1st Floor, Sonawala Lane, Goregaon East,
Mumbai City Maharashtra - 400063

NURECA LIMITED			
Office Number 101, 1st Floor Udyog Bhavan Sonawala Lane, Goregaon (East), Mumbai - 400063, Maharashtra, India Tel: +91 -172-5292900, E-mail: cs@nureca.com, Website: www.nureca.com Corporate Identification Number: L24304MH2016PLC320868			
(Amount in INR million, unless otherwise stated)			
Standalone Statement of Assets and Liabilities			
Sr. No.	Particulars	As at	
		31 March 2025 (Audited)	31 March 2024 (Audited)
(1)	Assets		
	Non-current assets		
	Property, plant and equipment	36.32	23.89
	Right-of-use assets	21.99	16.92
	Intangible assets	19.65	22.51
	Financial assets		
	- Investments		
	- Loans	30.56	30.56
	- Other financial assets	-	6.27
	Deferred tax assets (net)	41.12	2.92
	Non-current tax assets (net)	33.73	48.78
	Other Non-Current Assets	14.34	-
	Total non-current assets	20.08	-
		217.79	151.85
(2)	Current assets		
	Inventories		
	Financial assets	355.48	287.58
	- Investments		
	- Loans	10.43	936.33
	- Trade receivables	6.18	-
	- Cash and cash equivalents	45.25	18.10
	- Bank balances other than cash and cash equivalents	31.88	139.60
	- Other financial assets	430.12	312.42
	Other current assets	829.52	83.28
		134.94	114.16
	Total current assets	1,843.80	1,891.47
	Total assets (1+2)	2,061.59	2,043.32
(1)	Equity and Liabilities		
	Equity		
	Equity share capital	100.00	100.00
	Other equity	1,824.79	1,828.59
(2)	Total equity	1,924.79	1,928.59
	Non-current liabilities		
	Financial liabilities		
	- Borrowings	10.47	3.26
(3)	- Lease liabilities	15.43	14.79
	Provisions	6.49	9.04
	Total non-current liabilities	32.39	27.09
	Current liabilities		
(3)	Financial liabilities		
	- Borrowings	4.76	0.75
	- Lease liabilities	10.51	5.53
	- Trade payables		
	- total outstanding dues of micro and small enterprises	2.38	1.49
	- total outstanding dues of creditors other than micro and small enterprises	54.18	47.63
	- Other financial liabilities	17.09	0.32
	Other current liabilities	13.27	22.33
	Provisions	2.22	1.61
	Current tax liabilities (net)	-	7.98
	Total current liabilities	104.41	87.64
	Total liabilities (2+3)	136.80	114.73
	Total equity and liabilities (1+2+3)	2,061.59	2,043.33

SAURABH GOYAL
Digitally signed by SAURABH GOYAL
Date: 2025.05.05 20:22:08 +05'30'

NURECA LIMITED

Correspondence Office : SCO 6-7-8, 1st Floor, Madhya Marg, Sector 9-D, Chandigarh 160009
Registered Office : 101 Office Number, Udyog Bhavan, 1st Floor, Sonawala Lane, Goregaon East, Mumbai City Maharashtra - 400063

NURECA LIMITED			
Office Number 101, 1st Floor Udyog Bhavan Sonawala Lane, Goregaon (East), Mumbai - 400063, Maharashtra, India			
Tel: +91 -172-5292900, E-mail: cs@nureca.com , Website: www.nureca.com			
Corporate Identification Number: L24304MH2016PLC320868			
(Amount in INR million, unless otherwise stated)			
Standalone Statement of Cash Flow			
Sr. No.	Particulars	For the	
		Year ended 31 March 2025 (Audited)	Year ended 31 March 2024 (Audited)
(A)	Cash flows from operating activities		
	(Loss)/Profit before tax for the period	(4.60)	(32.69)
	Adjustments for:		
	Depreciation and amortization expense	21.53	22.42
	Income on unwinding of security deposits	(0.02)	(0.13)
	Unrealized foreign exchange (gain)	(0.59)	(0.01)
	Finance costs	11.15	4.60
	Provision for doubtful advances	3.09	1.27
	Interest income	(76.71)	(39.42)
	Derivative measured at FVTPL	2.70	0.20
	Gain on Sale of property plant and equipment (net)	(0.22)	-
	Fair value changes and net gain/loss on investment	(42.90)	(58.68)
	Operating cash flows before working capital changes	(86.57)	(102.44)
	Working capital adjustments		
	(Increase)/Decrease in inventories	(67.90)	40.67
	(Increase)/Decrease in trade receivables	(27.15)	23.31
	Increase/(decrease) in trade payables	8.03	(0.71)
	(Increase)/ decrease in other assets	(26.10)	(7.50)
	Increase in other financial liabilities	17.00	-
	Decrease in other financial asset	14.70	-
	Increase/ (decrease) in other current liabilities	(9.06)	0.30
	Increase in provisions	1.90	1.51
	Cash used in operating activities	(175.15)	(44.86)
	Income tax (paid)/refunded net	(10.33)	14.89
	Net cash used in operating activities	(185.48)	(29.97)
(B)	Cash flows from investing activities		
	Purchase of property, plant and equipment	(19.80)	(4.97)
	Proceed from sale of property, plant and equipment	0.29	-
	Advance given for purchase of land	(20.08)	-
	Interest income received	49.14	97.47
	Purchase of investment	(394.25)	(2,040.20)
	Proceeds from sale of investment	1,363.05	1,753.46
	Loan given to subsidiary	0.09	(8.74)
	Repayment of loan by subsidiary	-	4.70
	Mark to market losses on derivative contract	(2.70)	0.20
	Investment in /Redemption of Fixed deposits (net)	(890.10)	376.44
	Net cash generated from /(used in) investing activities (B)	85.64	178.36
(C)	Cash flows from financing activities		
	Payment of lease liabilities (Principal)	(10.71)	(12.22)
	Payment of lease liabilities (Interest)	(2.75)	(2.31)
	Finance cost	(5.58)	(2.27)
	Proceed from non-current borrowings	14.41	4.30
	Repayment of non current borrowings	(3.25)	(0.29)
(A+B+C)	Net cash used in financing activities	(7.88)	(12.79)
	Net (decrease)/ increase in cash and cash equivalents	(107.72)	135.60
	Cash and cash equivalents at the beginning of the year	139.60	4.00
	Cash and cash equivalents at the end of the period	31.88	139.60
	Components of cash and cash equivalents		
	Cash on hand	-	-
	Balances with banks:		
	- In current accounts	31.88	12.10
	- Fixed deposits with original maturity up to three months	-	127.50
	Total cash and cash equivalents	31.88	139.60

SAURABH GOYAL Digitally signed by
SAURABH GOYAL
Date: 2025.05.05
20:22:25 +05'30'

NURECA LIMITED

Correspondence Office : SCO 6-7-8, 1st Floor, Madhya Marg, Sector 9-D, Chandigarh 160009
Registered Office : 101 Office Number, Udyog Bhavan, 1st Floor, Sonawala Lane, Goregaon East,
Mumbai City Maharashtra - 400063

NURECA LIMITED	
Office Number 101, 1st Floor Udyog Bhavan Sonawala Lane, Goregaon (East), Mumbai - 400063, Maharashtra, India Tel: +91 -172-5292900, E-mail: cs@nureca.com, Website: www.nureca.com Corporate Identification Number: L24304MH2016PLC320868	
Notes to the Audited standalone financial results:	
<ol style="list-style-type: none"> 1 The above audited standalone financial results for the quarter and year ended 31 March 2025 as reviewed by the Audit Committee, have been approved at the meeting of the Board of Directors held on 05 May 2025. The audit report of the Statutory Auditors is being filed with the BSE Limited and National Stock Exchange of India Limited. For more details, visit the investor relation section of our website www.nureca.com and financials results at corporate section at www.bseindia.com and www.nseindia.com. 2 The business of the Company falls within single line of business i.e. business of home healthcare and wellness products. Accordingly, the segment related disclosures as per IND AS 108 are not applicable to the company. 3 The figures for the last quarter ended March 31, 2025 and the corresponding quarter ended in the previous year, are the balancing figures between audited figures in respect of the full financial year and the published, year to date, figures up to the end of the third quarter of the relevant financial year. Also, the figures up to the end of the third quarter had only been reviewed and not subject to audit. 4 The Board of Directors of the Company, in its meeting dated May 5, 2025, has principally decided to approve the merger of Nureca Technologies Private Limited (wholly owned subsidiary) with Nureca Limited (holding company) subject to necessary statutory and regulatory approvals under applicable laws to be taken in due course. 	<p>For and on behalf of Board of Directors of SAURABH GOYAL Digitally signed by SAURABH GOYAL Date: 2025.05.05 20:22:40 +05'30' Saurabh Goyal (Managing Director) DIN : 00136037</p>
Place: Guangzhou (China) Date: 05 May 2025	

NURECA LIMITED

Correspondence Office : SCO 6-7-8, 1st Floor, Madhya Marg, Sector 9-D, Chandigarh 160009
Registered Office : 101 Office Number, Udyog Bhavan, 1st Floor, Sonawala Lane, Goregaon East, Mumbai City Maharashtra - 400063

Independent Auditor's Report

To the Board of Directors of Nureca Limited

Report on the audit of the Standalone Annual Financial Results

Opinion

We have audited the accompanying standalone annual financial results of Nureca Limited (hereinafter referred to as the "Company") for the year ended 31 March 2025, attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("Listing Regulations").

In our opinion and to the best of our information and according to the explanations given to us, the aforesaid standalone annual financial results:

- a. are presented in accordance with the requirements of Regulation 33 of the Listing Regulations in this regard; and
- b. give a true and fair view in conformity with the recognition and measurement principles laid down in the applicable Indian Accounting Standards, and other accounting principles generally accepted in India, of the net loss and other comprehensive income and other financial information for the year ended 31 March 2025.

Basis for Opinion

We conducted our audit in accordance with the Standards on Auditing ("SAs") specified under section 143(10) of the Companies Act, 2013 ("the Act"). Our responsibilities under those SAs are further described in the *Auditor's Responsibilities for the Audit of the Standalone Annual Financial Results* section of our report. We are independent of the Company, in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the financial statements under the provisions of the Act, and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence obtained by us, is sufficient and appropriate to provide a basis for our opinion on the standalone annual financial results.

Management's and Board of Directors' Responsibilities for the Standalone Annual Financial Results

These standalone annual financial results have been prepared on the basis of the standalone annual financial statements.

The Company's Management and the Board of Directors are responsible for the preparation and presentation of these standalone annual financial results that give a true and fair view of the net profit/loss and other comprehensive income and other financial information in accordance with the recognition and measurement principles laid down in Indian Accounting Standards prescribed under Section 133 of the Act and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and the design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring accuracy and completeness of the accounting records, relevant to the preparation and

Registered Office:

B S R & Co. (a partnership firm with Registration No. BA61223) converted into B S R & Co. LLP (a Limited Liability Partnership with LLP Registration No. AAB-8181) with effect from October 14, 2013

14th Floor, Central B Wing and North C Wing, Nesco IT Park 4, Nesco Center, Western Express Highway, Goregaon (East), Mumbai - 400063

Independent Auditor's Report (Continued)

Nureca Limited

presentation of the standalone annual financial results that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the standalone annual financial results, the Management and the Board of Directors are responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

The Board of Directors are responsible for overseeing the Company's financial reporting process.

Auditor's Responsibilities for the Audit of the Standalone Annual Financial Results

Our objectives are to obtain reasonable assurance about whether the standalone annual financial results as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these standalone annual financial results.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the standalone annual financial results, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under Section 143(3) (i) of the Act, we are also responsible for expressing our opinion through a separate report on the complete set of financial statements on whether the company has adequate internal financial controls with reference to financial statements in place and the operating effectiveness of such controls.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures in the standalone annual financial results made by the Management and Board of Directors.
- Conclude on the appropriateness of the Management's and Board of Directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the appropriateness of this assumption. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the standalone annual financial results or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the standalone annual financial results, including the disclosures, and whether the standalone annual financial results represent the underlying transactions and events in a manner that achieves fair presentation.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

Independent Auditor's Report (Continued)

Nureca Limited

Other Matter

- a. The standalone annual financial results include the results for the quarter ended 31 March 2025 being the balancing figure between the audited figures in respect of the full financial year and the published unaudited year to date figures up to the third quarter of the current financial year which were subject to limited review by us.

For **B S R & Co. LLP**

Chartered Accountants

Firm's Registration No.:101248W/W-100022

**Ankush
Goel**

Digitally signed by
Ankush Goel
Date: 2025.05.05
20:39:16 +05'30'

Ankush Goel

Partner

Gurugram

05 May 2025

Membership No.: 505121

UDIN:25505121BMLCOG1974

NURECA LIMITED						
Office Number 101, 1st Floor Udyog Bhavan Sonawala Lane, Goregaon (East), Mumbai - 400063, Maharashtra, India Tel: +91 -172-5292900, E-mail: cs@nureca.com, Website: www.nureca.com Corporate Identification Number: L24304MH2016PLC320868						
(Amount in INR million, unless otherwise stated)						
Statement of Audited Consolidated Financial Results for the quarter and year ended 31st March 2025						
	Particulars	Quarter ended			Year ended	
		31 March 2025 Refer note 3	31 December 2024 (Unaudited)	31 March 2024 Refer note 3	31 March 2025 (Audited)	31 March 2024 (Audited)
1	Revenue from operations	317.40	264.63	169.70	1,096.61	919.28
2	Other income	19.93	14.77	(12.59)	124.35	105.14
3	Total income (1+2)	337.33	279.40	157.11	1,220.96	1,024.42
4	Expenses					
	Cost of material consumed	38.55	39.95	10.46	112.91	97.60
	Purchase of stock-in-trade	251.59	143.15	75.04	636.76	464.70
	Changes in inventories of stock-in-trade and finished goods	(100.43)	(17.79)	26.31	(69.55)	43.85
	Employee benefits expense	42.70	38.44	30.68	153.07	122.01
	Finance costs	6.20	1.75	1.79	12.14	4.89
	Depreciation and amortization expense	5.22	5.40	6.00	23.38	23.62
	Other expenses	72.99	101.02	71.55	338.82	293.19
	Total expenses	316.82	311.92	221.83	1,207.53	1,049.86
5	Profit/(Loss) before income tax (3-4)	20.51	(32.52)	(64.72)	13.43	(25.44)
6	Tax expense					
	- Current tax	(19.34)	(1.99)	0.08	(8.17)	15.60
	- Deferred tax	15.18	(2.52)	(23.34)	13.14	(23.10)
7	Profit/(Loss) after income tax (5-6)	24.67	(28.01)	(41.46)	8.46	(17.94)
8	Other comprehensive income/(loss)					
A	(i) Item that will not be reclassified to profit or loss	4.03	0.13	0.93	4.43	0.35
	(ii) Income tax relating to items that will not be reclassified to profit or loss	(0.97)	(0.03)	(0.25)	(1.07)	(0.10)
B	(i) Item that will be reclassified to profit or loss	(0.00)	(0.06)	(0.00)	(0.08)	(0.03)
	(ii) Income tax relating to items that will be reclassified to profit or loss	-	-	-	-	-
	Total other comprehensive income/(loss) for the period (net of tax)	3.06	0.04	0.68	3.28	0.22
9	Total comprehensive income/(loss) for the period (7+8)	27.73	(27.97)	(40.78)	11.74	(17.72)
10	Earning/(Loss) per share of Rs. 10 each - Basic and diluted (in rupees) (not annualized)	2.47	(2.80)	(4.15)	0.85	(1.79)
11	Paid-up equity share capital (Face value of share - Rs.10 each)	100.00	100.00	100.00	100.00	100.00
12	Other equity				1,842.85	1,831.11
	See accompanying notes to the audited consolidated financial results					

SAURAB
H GOYAL

Digitally signed
by SAURABH
GOYAL
Date: 2025.05.05
20:19:25 +05'30'

NURECA LIMITED

Correspondence Office : SCO 6-7-8, 1st Floor, Madhya Marg, Sector 9-D, Chandigarh 160009
Registered Office : 101 Office Number, Udyog Bhavan, 1st Floor, Sonawala Lane, Goregaon East,
Mumbai City Maharashtra - 400063

NURECA LIMITED			
Office Number 101, 1st Floor Udyog Bhavan Sonawala Lane, Goregaon (East), Mumbai - 400063, Maharashtra, India Tel: +91 -172-5292900, E-mail: cs@nureca.com, Website: www.nureca.com Corporate Identification Number: L24304MH2016PLC320868			
(Amount in INR million, unless otherwise stated)			
Consolidated Statement of Assets and Liabilities			
Sr. No.	Particulars	As at	
		31 March 2025 (Audited)	31 March 2024 (Audited)
	Assets		
(1)	Non-current assets		
	Property, plant and equipment	48.14	31.20
	Right-of-use assets	21.99	16.92
	Intangible assets	19.83	22.97
	Capital work in progress	-	2.70
	Financial assets		
	- Other financial assets	41.12	2.92
	Deferred tax assets (net)	34.75	49.02
	Non current tax assets (net)	14.32	-
	Other Non-Current Assets	20.08	-
	Total non-current assets	200.23	125.73
(2)	Current assets		
	Inventories	399.18	308.51
	Financial assets		
	- Investments	10.43	936.33
	- Trade receivables	33.22	16.15
	- Cash and cash equivalents	32.41	140.62
	- Bank balances other than cash and cash equivalents	430.12	312.42
	- Other financial assets	829.51	83.28
	Other current assets	164.66	128.61
	Total current assets	1,899.53	1,925.92
	Total assets (1+2)	2,099.76	2,051.65
	Equity and Liabilities		
(1)	Equity		
	Equity share capital	100.00	100.00
	Other equity	1,842.85	1,831.11
	Total equity	1,942.85	1,931.11
(2)	Non-current liabilities		
	Financial liabilities		
	- Borrowings	10.47	3.26
	- Lease liabilities	15.43	14.79
	Provisions	7.02	9.76
	Total non-current liabilities	32.92	27.81
(3)	Current liabilities		
	Financial liabilities		
	- Borrowings	13.25	1.58
	- Lease liabilities	10.51	5.53
	- Trade payables		
	- total outstanding dues of micro and small enterprises	11.63	5.02
	- total outstanding dues of creditors other than micro and small enterprises	53.96	46.72
	- Other financial liabilities	18.17	0.62
	Other current liabilities	13.42	23.22
	Provisions	2.30	1.68
	Current tax liabilities (net)	0.75	8.36
	Total current liabilities	123.99	92.73
	Total liabilities (2+3)	156.91	120.54
	Total equity and liabilities (1+2+3)	2,099.76	2,051.65

SAURAB H GOYAL Digitally signed by SAURABH GOYAL
Date: 2025.05.05 20:20:07 +05'30'

NURECA LIMITED

Correspondence Office : SCO 6-7-8, 1st Floor, Madhya Marg, Sector 9-D, Chandigarh 160009
Registered Office : 101 Office Number, Udyog Bhavan, 1st Floor, Sonawala Lane, Goregaon East, Mumbai City Maharashtra - 400063

Phone No: +91 172 5292900, GILL 8473 444001651 0300000

NURECA LIMITED	
Office Number 101, 1st Floor Udyog Bhavan Sonawala Lane, Goregaon (East), Mumbai - 400063, Maharashtra, India	
Tel: +91 - 172-5292900, E-mail: cs@nureca.com , Website: www.nureca.com	
Corporate Identification Number: L24304MH2016PLC320868	

Consolidated Statement of Cash Flow Statement			
(Amount in INR million, unless otherwise stated)			
Sr. No.	Particulars	Year ended 31 March 2025 (Audited)	Year ended 31 March 2024 (Audited)
	Cash flows from operating activities		
	Profit/(loss) before tax for the period	13.43	(25.44)
	Adjustments for:		
	Depreciation and amortization expense	23.38	23.62
	Income on unwinding of security deposits	(0.02)	(0.13)
	Unrealized foreign exchange (gain)	(0.59)	(0.01)
	Finance costs	12.14	4.89
	Other receivable written off	0.50	1.02
	Provision for doubtful advance	0.75	0.10
	Interest income	(76.20)	(38.41)
	Derivative measured at FVTPL	(2.70)	-
	Gain on Sale of property plant and equipment	(0.22)	-
	Change in fair value of financial assets at FVTPL	(42.90)	(58.68)
	Operating cash flows before working capital changes	(72.43)	(93.04)
	Working capital adjustments		
	Decrease/(increase) in inventories	(90.67)	36.26
	Decrease/(increase) in trade receivables	(17.07)	27.05
	Increase in trade payables	14.45	1.85
	Decrease/(increase) in other assets	(21.11)	(13.45)
	Increase in other financial liabilities	17.25	0.19
	(Decrease)/Increase in other current liabilities	(9.80)	0.62
	Increase in provisions	2.31	0.91
	Cash used in operating activities	(177.07)	(39.61)
	Income tax (paid)/refunded	(13.76)	12.49
(A)	Net cash used in operating activities	(190.83)	(27.12)
	Cash flows from investing activities		
	Purchase of property, plant and equipment	(23.15)	(10.86)
	Proceed from sale of property, plant and equipment	0.29	-
	Advance given for purchase of land	(20.08)	-
	Interest income received	76.20	96.94
	Purchase of investments	(394.25)	(2,015.52)
	Proceeds from sale of investments	1,363.05	1,728.74
	Investment in /Redemption of Fixed deposits (net)	(917.67)	376.45
(B)	Net cash (used in)/generated from investing activities	84.39	175.76
	Cash flows from financing activities		
	Payment of lease liabilities (principal)	(10.71)	(12.22)
	Payment of lease liabilities (interest)	(2.75)	(2.31)
	Finance costs paid	(7.11)	(2.51)
	Proceeds from non-current borrowings	14.41	4.30
	Repayment of non current borrowings	(1.96)	-
	Proceeds from current borrowings (net)	6.43	(0.29)
(C)	Net cash generated from/(used in) financing activities	(1.69)	(13.03)
(A+B+C)	Net (decrease)/increase in cash and cash equivalents	(108.13)	135.61
	Effect of exchange rate fluctuations on cash & cash equivalents held in foreign currency	(0.08)	(0.03)
	Cash and cash equivalents at the beginning of the period	140.62	5.04
	Cash and cash equivalents at the end of the period	32.41	140.62
	Components of cash and cash equivalents		
	Balances with banks:		
	- In current accounts	32.41	13.12
	- Fixed deposits with original maturity up to three months	-	127.50
	Total cash and cash equivalents	32.41	140.62

SAURAB H GOYAL Digitally signed by
SAURABH GOYAL
Date: 2025.05.05
20:20:25 +05'30'

NURECA LIMITED

Correspondence Office : SCO 6-7-8, 1st Floor, Madhya Marg, Sector 9-D, Chandigarh 160009
Registered Office : 101 Office Number, Udyog Bhavan, 1st Floor, Sonawala Lane, Goregaon East,
Mumbai City Maharashtra - 400063

NURECA LIMITED	
Office Number 101, 1st Floor Udyog Bhavan Sonawala Lane, Goregaon (East), Mumbai - 400063, Maharashtra, India Tel: +91 -172-5292900, E-mail: cs@nureca.com , Website: www.nureca.com Corporate Identification Number: L24304MH2016PLC320868	
Notes to the audited consolidated financial results:	
<ol style="list-style-type: none"> The above audited consolidated financial results for the year ended 31 March 2025 as reviewed by the Audit Committee, have been approved at the meeting of the Board of Directors held on 5 May 2025. The Audited report of the Statutory Auditors is being filed with the BSE Limited and National Stock Exchange of India Limited. For more details, visit the investor relation section of our website www.nureca.com and financials results at corporate section at www.bseindia.com and www.nseindia.com. The business of the Group falls within single line of business i.e. business of home healthcare and wellness products. The figures for the last quarter ended March 31, 2025 are the balancing figures between audited figures in respect of the full financial year and the published year to date figures up to the end of the third quarter of the relevant financial year. Also, the figures up to the end of the third quarter had only been reviewed and not subject to audit. The Board of Directors of the Holding Company, in its meeting dated May 5, 2025, has principally decided to approve the merger of Nureca Technologies Private Limited (wholly owned subsidiary) with Nureca Limited (holding company) subject to necessary statutory and regulatory approvals under applicable laws to be taken in due course. The audited consolidated financial results include the financials results of the Parent company and its subsidiaries (collectively referred as 'the Group') as below : <div> <p>Parent Company Nureca Limited - Incorporated in India</p> <p>Subsidiaries i) Nureca Technologies Private Limited - Incorporated in India ii) Nureca Healthcare Private Limited - Incorporated in India iii) Nureca Inc. USA</p> </div> 	
Place: Guangzhou (China) Date: 5 May 2025	<p>For and on behalf of Board of Directors of Nureca Limited</p> <p>SAURABH GOYAL</p> <p><small>Digitally signed by SAURABH GOYAL Date: 2025.05.05 20:20:44 +05'30'</small></p> <p>Saurabh Goyal (Managing Director) DIN : 00136037</p>

NURECA LIMITED

Correspondence Office : SCO 6-7-8, 1st Floor, Madhya Marg, Sector 9-D, Chandigarh 160009
Registered Office : 101 Office Number, Udyog Bhavan, 1st Floor, Sonawala Lane, Goregaon East,
Mumbai City Maharashtra - 400063

Independent Auditor's Report

To the Board of Directors of Nureca Limited

Report on the audit of the Consolidated Annual Financial Results

Opinion

We have audited the accompanying consolidated annual financial results of Nureca Limited (hereinafter referred to as the "Holding Company") and its subsidiaries (Holding Company and its subsidiaries together referred to as "the Group"), for the year ended 31 March 2025, attached herewith, being submitted by the Holding Company pursuant to the requirement of Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("Listing Regulations").

In our opinion and to the best of our information and according to the explanations given to us and based on the consideration of reports of other auditors on separate financial results of the subsidiaries, the aforesaid consolidated annual financial results:

- include the annual financial results of the entities mentioned in Annexure I;
- are presented in accordance with the requirements of Regulation 33 of the Listing Regulations in this regard; and
- give a true and fair view in conformity with the recognition and measurement principles laid down in the applicable Indian Accounting Standards, and other accounting principles generally accepted in India, of consolidated net profit and other comprehensive income and other financial information of the Group for the year ended 31 March 2025.

Basis for Opinion

We conducted our audit in accordance with the Standards on Auditing ("SAs") specified under section 143(10) of the Companies Act, 2013 ("the Act"). Our responsibilities under those SAs are further described in the *Auditor's Responsibilities for the Audit of the Consolidated Annual Financial Results* section of our report. We are independent of the Group in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the financial statements under the provisions of the Act, and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence obtained by us, along with the consideration of reports of the other auditors referred to in sub paragraph no. a of the "Other Matters" paragraph below, is sufficient and appropriate to provide a basis for our opinion on the consolidated annual financial results.

Management's and Board of Directors' Responsibilities for the Consolidated Annual Financial Results

These consolidated annual financial results have been prepared on the basis of the consolidated annual financial statements.

The Holding Company's Management and the Board of Directors are responsible for the preparation and presentation of these consolidated annual financial results that give a true and fair view of the consolidated net profit/ loss and other comprehensive income and other financial information of the Group in accordance with the recognition and measurement principles laid down in Indian Accounting Standards prescribed under Section 133 of the Act read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations.

Registered Office:

B S R & Co. (a partnership firm with Registration No. BA61223) converted into B S R & Co. LLP (a Limited Liability Partnership with LLP Registration No. AAB-8181) with effect from October 14, 2013

14th Floor, Central B Wing and North C Wing, Nesco IT Park 4, Nesco Center, Western Express Highway, Goregaon (East), Mumbai - 400063

Independent Auditor's Report (Continued)**Nureca Limited**

The respective Management and Board of Directors of the companies included in the Group are responsible for maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of each company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and the design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring accuracy and completeness of the accounting records, relevant to the preparation and presentation of the consolidated annual financial results that give a true and fair view and are free from material misstatement, whether due to fraud or error, which have been used for the purpose of preparation of the consolidated annual financial results by the Management and the Board of Directors of the Holding Company, as aforesaid.

In preparing the consolidated annual financial results, the respective Management and the Board of Directors of the companies included in the Group are responsible for assessing the ability of each company to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the respective Board of Directors either intends to liquidate the company or to cease operations, or has no realistic alternative but to do so.

The respective Board of Directors of the companies included in the Group is responsible for overseeing the financial reporting process of each company.

Auditor's Responsibilities for the Audit of the Consolidated Annual Financial Results

Our objectives are to obtain reasonable assurance about whether the consolidated annual financial results as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these consolidated annual financial results.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the consolidated annual financial results, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under Section 143(3) (i) of the Act, we are also responsible for expressing our opinion through a separate report on the complete set of financial statements on whether the company has adequate internal financial controls with reference to financial statements in place and the operating effectiveness of such controls.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures in the consolidated annual financial results made by the Management and Board of Directors.
- Conclude on the appropriateness of the Management's and Board of Directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the appropriateness of this assumption. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the consolidated annual financial results or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Group to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the consolidated annual financial results, including the disclosures, and whether the consolidated annual financial results represent the underlying transactions and events in a manner that achieves fair presentation.

Independent Auditor's Report (Continued)

Nureca Limited

- Obtain sufficient appropriate audit evidence regarding the financial statements of the entities within the Group to express an opinion on the consolidated annual financial results. We are responsible for the direction, supervision and performance of the audit of financial statements of such entities included in the consolidated annual financial results of which we are the independent auditor. For the other entities included in the consolidated annual financial results, which have been audited by other auditors, such other auditors remain responsible for the direction, supervision and performance of the audits carried out by them. We remain solely responsible for our audit opinion. Our responsibilities in this regard are further described in sub paragraph no. a and b of the "Other Matters" paragraph in this audit report.

We communicate with those charged with governance of the Holding Company annual financial results of which we are the independent auditors regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

We also performed procedures in accordance with the circular No CIR/CFD/CMD1/44/2019 issued by the Securities and Exchange Board of India under Regulation 33(8) of the Listing Regulations, to the extent applicable.

Other Matters

- a. The consolidated annual financial results include the audited financial results of two subsidiaries, whose financials results reflect total assets (before consolidation adjustments) of Rs. 107.19 millions as at 31 March 2025, total revenue (before consolidation adjustments) of Rs. 229 millions and total net profit after tax (before consolidation adjustments) of Rs. 14.06 millions and net cash outflows (before consolidation adjustments) of Rs 0.50 millions for the year ended on that date, as considered in the consolidated annual financial results, which have been audited by their respective independent auditors. The independent auditor's reports on financial statements of these entities have been furnished to us by the management.

Our opinion on the consolidated annual financial results, in so far as it relates to the amounts and disclosures included in respect of these entities, is based solely on the reports of such auditors and the procedures performed by us are as stated in paragraph above.

Our opinion on the consolidated annual financial results is not modified in respect of the above matter with respect to our reliance on the work done and the reports of the other auditors.

- b. The consolidated annual financial results include the unaudited financial results of one subsidiary, whose financial statements reflect total assets (before consolidation adjustments) of Rs. 0.76 millions as at 31 March 2025, total revenue (before consolidation adjustments) of Rs. 2.39 millions, total net profit after tax (before consolidation adjustments) of Rs. 2.12 millions and net cash inflows (before consolidation adjustments) of Rs 0.01 millions for the year ended on that date, as considered in the consolidated annual financial results. This unaudited financial results has been furnished to us by the Board of Directors.

Our opinion on the consolidated annual financial results, in so far as it relates to the amounts and disclosures included in respect of this subsidiary, is based solely on such financial statement. In our opinion and according to the information and explanations given to us by the Board of Directors, this financial results is not material to the Group.

Our opinion on the consolidated annual financial results is not modified in respect of the above matter with respect to the financial results certified by the Board of Directors.

- c. The consolidated annual financial results include the results for the quarter ended 31 March 2025 being the balancing figure between the audited figures in respect of the full financial year and the published unaudited year to date figures up to the third quarter of the current financial year which

Independent Auditor's Report (Continued)

Nureca Limited

were subject to limited review by us.

For **B S R & Co. LLP**

Chartered Accountants

Firm's Registration No.:101248W/W-100022

**Ankush
Goel** Digitally signed
by Ankush Goel
Date: 2025.05.05
20:39:43 +05'30'

Ankush Goel

Partner

Gurugram

05 May 2025

Membership No.: 505121

UDIN:25505121BMLCOJ7910

Independent Auditor's Report (Continued)**Nureca Limited****Annexure I**

List of entities included in consolidated annual financial results.

Sr. No	Name of component	Relationship
1	Nureca Limited	Holding Company (incorporated in India)
2	Nureca Technologies Private Limited	Subsidiary Company (incorporated in India)
3	Nureca Healthcare Private Limited	Subsidiary Company (incorporated in India)
4	Nureca Inc	Subsidiary Company (incorporated in USA)

Declaration pursuant to Regulation 33 (3) (d) of the Listing Regulations

I, Naresh Gupta, Chief Financial Officer, hereby declare that the Statutory Auditors of the Company, M/5 B S R & Co. LLP, Chartered Accountants (Firm Registration No.101248W/W-100022} have issued unmodified opinion on annual audited Financial Results (Standalone and Consolidated) of the Company, for the Financial Year ended 31st March 2025, which have been approved by the Board of Directors of the Company at the meeting held today i.e May 05, 2025.



Naresh Gupta
Chief Financial Officer
Date : 05th May, 2025